3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl-6'-ylamine | 4945-46-4

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: 3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl-6'-ylamine
• 英文别名: N-(piperidine-1-yl)-pyridine-2,6-diamine；6-(piperidin-1-yl)pyridin-2-amine；2-amino-6-(1-piperidinyl)pyridine；3,4,5,6-tetrahydro-2H-[1,2']bipyridyl-6'-ylamine；3,4,5,6-Tetrahydro-2H-[1,2']bipyridyl-6'-ylamin；6-piperidin-1-yl-pyridin-2-ylamine；6-piperidin-1-ylpyridin-2-amine
• CAS: 4945-46-4
• 化学式: C₁₀H₁₅N₃
• 分子量: 177.249
• InChiKey: RCGLVZGTHFCFMW-UHFFFAOYSA-N

物化性质

• 熔点：
  38-39 °C
• 沸点：
  202 °C(Press: 30 Torr)
• 密度：
  1.127±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.8
• 重原子数：
  13
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  42.2
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl-6'-ylamine 在 碳酸氢钠 作用下， 以 四氢呋喃 、 二氯甲烷 、 水 为溶剂， 反应 2.0h， 生成 2-(2-hydroxy-2-(4-methylthiazol-2-yl)propanoyl)-N-(6-(piperidin-1-yl)pyridin-2-yl)hydrazine-1-carbothioamide
  参考文献：
  名称：

  Design, Synthesis, and Evaluation of New Thiadiazole-Based Direct Inhibitors of Enoyl Acyl Carrier Protein Reductase (InhA) for the Treatment of Tuberculosis

  摘要：

  Mycobacterial enoyl acyl carrier protein reductase (InhA) is a clinically validated target for the treatment of tuberculosis infections, a disease that still causes the death of at least a million people annually. A known class of potent, direct, and competitive InhA inhibitors based on a tetracyclic thiadiazole structure has been shown to have in vivo activity in murine models of tuberculosis infection. On the basis of this template, we have here explored the medicinal chemistry of truncated analogues that have only three aromatic rings. In particular, compounds 8b, 8d, 8f, 8l, and 8n show interesting features, including low nanomolar InhA IC50, submicromolar antimycobacterial potency, and improved physicochemical profiles in comparison with the tetracyclic analogues. From this series, 8d is identified as having the best balance of potency and properties, whereby the resolved 8d S-enatiomer shows encouraging in vivo efficacy.

  DOI：

  10.1021/jm501029r
• 作为产物：
  描述：

  哌啶 、 2-氨基-6-溴吡啶 在 copper(l) iodide 作用下， 以 水 为溶剂， 反应 5.0h， 以95%的产率得到3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl-6'-ylamine
  参考文献：
  名称：

  微波辅助铜催化卤代吡啶的合成实用的2,6-二氨基吡啶取代基

  摘要：

  据报道，利用一系列的2，6-二卤代和2-氨基-6-卤代吡啶前体，进行了微波辅助的铜催化的胺化反应。使用该方法，被芳基或烷基胺一个或两个卤素选择性取代物2-6小时内用80和225之间的温度下℃下，得到良好的2,6-二氨基吡啶，以优异的分离产率来实现的。该反应允许离析物和不同之间容易变化Ñ -substitutions。目标化合物可用于被用作过渡金属络合物PNP钳配体的双-磷酸化2,6-二氨基吡啶合成有价值的前体。

  DOI：

  10.1016/j.tet.2015.08.042

文献信息

• GAMMA SECRETASE MODULATORS
  申请人：Baumann Karlheinz

  公开号：US20110190269A1

  公开（公告）日：2011-08-04

  The invention relates to compounds of formula wherein R 1 , R 1′ , R 2 , R 3 , n, A, and hetaryl are defined herein or to pharmaceutically active acid addition salts thereof. The present compounds of formula I are modulators for amyloid beta and thus, they may be useful for the treatment or prevention of a disease associated with the deposition of β-amyloid in the brain, in particular Alzheimer's disease, and other diseases such as cerebral amyloid angiopathy, hereditary cerebral hemorrhage with amyloidosis, Dutch-type (HCHWA-D), multi-infarct dementia, dementia pugilistica and Down syndrome.

  该发明涉及以下式的化合物 其中R 1 ，R 1′ ，R 2 ，R 3 ，n，A和hetaryl在此处定义，或其药用活性酸盐。式I的这些化合物是淀粉样蛋白β的调节剂，因此它们可能对与大脑中β-淀粉样蛋白沉积相关的疾病的治疗或预防有用，特别是阿尔茨海默病，以及其他疾病，如脑淀粉样血管病，遗传性脑出血伴有淀粉样变性，荷兰型（HCHWA-D），多梗死性痴呆，拳击性痴呆和唐氏综合征。
• Substituted alkylamine derivatives and methods of use
  申请人：Amgen Inc.

  公开号：US20030225106A1

  公开（公告）日：2003-12-04

  Selected amines are effective for prophylaxis and treatment of diseases, such as angiogenesis mediated diseases. The invention encompasses novel compounds, analogs, prodrugs and pharmaceutically acceptable salts thereof, pharmaceutical compositions and methods for prophylaxis and treatment of diseases and other maladies or conditions involving, cancer and the like. The subject invention also relates to processes for making such compounds as well as to intermediates useful in such processes.

  选定的胺对预防治疗疾病有效，如血管生成介导的疾病。本发明包括新的化合物、类似物、前药和药用可接受的盐，药物组合物和预防治疗疾病和其他疾病或状况的方法，包括癌症等。本发明还涉及制造这类化合物的过程以及在此类过程中有用的中间体。
• IMIDAZOPYRIDAZINE COMPOUNDS
  申请人：Hoffmann-La Roche Inc.

  公开号：US20130109661A1

  公开（公告）日：2013-05-02

  The present invention relates to the use of novel compounds of formula I: wherein all variable substituents are defined as described herein, which are SYK inhibitors and are useful for the treatment of auto-immune and inflammatory diseases.

  本发明涉及使用以下公式I的新化合物： 其中所有可变取代基均如本文所述定义，这些化合物是SYK抑制剂，可用于治疗自免疫和炎症性疾病。
• [EN] IMIDAZOPYRIDAZINE COMPOUNDS<br/>[FR] COMPOSÉS D'IMIDAZOPYRIDAZINE
  申请人：HOFFMANN LA ROCHE

  公开号：WO2013064445A1

  公开（公告）日：2013-05-10

  The present invention relates to the use of novel compounds of formula (I): wherein all variable substituents are defined as described herein, which are SYK inhibitors and are useful for the treatment of auto-immune and inflammatory diseases.

  本发明涉及使用以下公式（I）的新化合物：其中所有可变取代基均如本文所述定义，这些化合物是SYK抑制剂，可用于治疗自免疫性和炎症性疾病。
• Thiazolyl urea compounds and methods of uses
  申请人：——

  公开号：US20020193405A1

  公开（公告）日：2002-12-19

  Selected novel urea compounds are effective for prophylaxis and treatment of diseases, such as cell proliferation or apoptosis mediated diseases. The invention encompasses novel compounds, analogs, prodrugs and pharmaceutically acceptable salts thereof, pharmaceutical compositions and methods for prophylaxis and treatment of diseases and other maladies or conditions involving stoke, cancer and the like. The subject invention also relates to processes for making such compounds as well as to intermediates useful in such processes.

  选定的新型尿素化合物对预防和治疗疾病有效，如细胞增殖或凋亡介导的疾病。该发明涵盖了新型化合物、类似物、前药和其药用可接受的盐，以及用于预防和治疗中风、癌症等疾病和其他疾病或病况的药物组合物和方法。该发明还涉及制备此类化合物的方法，以及在这些过程中有用的中间体。